Get access

Levothyroxine dose following thyroidectomy is affected by more than just body weight

Authors

  • Kara Meinke Baehr MD,

    1. Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska
    Search for more papers by this author
  • Elizabeth Lyden MS,

    1. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A
    Search for more papers by this author
  • Kelly Treude BS,

    1. Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska
    Search for more papers by this author
  • Judi Erickson RN,

    1. Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska
    Search for more papers by this author
  • Whitney Goldner MD

    Corresponding author
    1. Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska
    • 984120 Nebraska Medical Center, Omaha, NE68198-4120
    Search for more papers by this author

  • This study used data from the Thyroid Tumor and Cancer Collaborative Registry (TCCR) at the University of Nebraska. The TCCR was jointly funded by the Department of Internal Medicine, the Department of Head and Neck Surgical Oncology, and the Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.

  • The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis:

To determine the factors that affect levothyroxine (LT4) requirements following thyroidectomy.

Study Design:

Retrospective study.

Methods:

This study evaluated 246 participants who had undergone total thyroidectomy and were on a stable dose of LT4. Actual weight–based (AWB) and ideal body weight–based (IBWB) LT4 dose requirements were analyzed, and other confounders including adherence, concurrent medications, comorbidities, female menopausal status, and hormone replacement therapy were examined.

Results:

A total of 205 women and 41 men were evaluated, with 48 (20%) benign and 198 (80%) malignant pathology findings. The mean AWB LT4 doses for men and premenopausal women were similar among members of the benign groups and similar among members of the malignant groups. There was a trend for lower dose LT4 in postmenopausal women off hormonal therapy (PM/NH) and on hormonal therapy (PM/H) in the benign group (1.4 and 1.6 μg/kg vs. 1.8 μg/kg in the men and premenopausal women) and a trend for lower dose LT4 in the PM/H women in the malignant group (1.9 μg/kgvs. 2.1 and 2.2 μg/kg in the men and premenopausal women), but they were not significant. However, PM/NH women required significantly less LT4 (1.7 μg/kg) than both the men (2.2 μg/kg) and premenopausal women (2.1 μg/kg) in the malignant group (P=.0006). The IBWB LT4 dosage was not statistically different between groups.

Conclusions:

LT4 dosage following thyroidectomy, calculated using actual body weight, can range from 1.4 to 2.2 μg/kg and is dependent on diagnosis (benign vs. malignant), goal TSH, sex, and menopausal status. Laryngoscope, 2012

Get access to the full text of this article

Ancillary